Incyte reports Q4 EPS $1.06, consensus $1.16

Reports Q4 revenue $1.01B, consensus $1B.”We delivered a strong 2023 with total net product and royalty revenues of $3.7B, increasing 14% versus 2022. In the fourth quarter, we achieved for the first time, a new milestone of $1 billion in total quarterly revenues, driven by the continued growth of Jakafi, ruxolitinib, and the successful launch of Opzelura, ruxolitinib, cream,” said Herve Hoppenot, Chief Executive Officer, Incyte. “Throughout 2023, we focused our R&D efforts on high potential programs and believe we are positioned to deliver more than ten high impact launches by 2030.”